Skip to main content
SpringerLink
Log in

Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: Peritoneal carcinomatosis is a difficult management problem, and intraperitoneal treatment approaches may provide an opportunity to intensify dose and minimize toxicity. The current experiments were conducted to characterize the cytotoxic effects of cisplatin (cDDP), tumor necrosis factor (TNF), and hyperthermia (HT) on a gastric cancer cell line in vitro under conditions achievable with intraperitoneal treatment.

Methods: Seoul National University gastric cancer cell line (SNU-5), a poorly differentiated gastric cancer cell line, was tested for sensitivity to various doses of cDDP, TNF, or combinations of the two at normothermia (37°C) or HT (42.5°C). The effect of TNF on cellular rates of cDDP accumulation, efflux, and cDDP-DNA adduct formation were evaluated using atomic absorbance spectrometry with Zeemen background correction.

Results: During a 2-h exposure to various doses of cDDP with HT, we observed a supraadditive cytotoxicity of SNU-5 with 1 to 50 µg/ml of TNF (p2=0.0001). In the presence of the three-agent combination (HT, TNF, and cDDP) we observed statistically significant increases in total cellular accumulation of cisplatin (p2=0.016); a nonsignificant decrease in cellular efflux of drug (p2=0.098); and a 40% increase in persistent cisplatin DNA damage as measured by atomic absorption spectrophotometry (p2=0.06). These patterns were specifically not seen with the combinations of cDDP and HT, or cDDP and TNF.

Conclusions: These data provide the experimental basis for the use of TNF and cDDP with HT in the treatment of gastric cancer and support the investigation of these agents in vivo in the regional treatment of peritoneal carcinomatosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fujimoto S, Shgrestha RD, Kokubun M, et al. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding.Ann Surg 1988;208:36–41.

    CAS  PubMed  Google Scholar 

  2. Fujimoto S, Shrestha RD, Kokuban M, et al. Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer.Ann Surg 1990;212:592–6.

    CAS  PubMed  Google Scholar 

  3. Fujimoto S, Shrestha RD, Kokubun M, et al. Clinical trial with surgery and intraperitoneal hyperthermic perfusion for peritoneal recurrence of gastrointestinal cancer.Cancer 1989;64:154–60.

    CAS  PubMed  Google Scholar 

  4. Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C.Cancer 1988;61:232–7.

    CAS  PubMed  Google Scholar 

  5. Alexander HR, Buell JF, Fraker DL. Rationale and clinical status of continuous hyperthermic peritoneal perfusion for the treatment of peritoneal carcinomatosis. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds.Principles and practice of oncology: PPO updates. Philadelphia: JB Lippincott, 1995:1–9.

    Google Scholar 

  6. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and Mitomycin C.Cancer Res 1980;40:1165–8.

    CAS  PubMed  Google Scholar 

  7. Yamaguchi A, Tsukioka Y, Fushida S, et al. Intraperitoneal hyperthermic treatment for peritoneal dissemination of colorectal cancers.Dis Colon Rectum 1992;35:964–8.

    Article  CAS  PubMed  Google Scholar 

  8. Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study.World J Surg 1994;18:150–5.

    Article  CAS  PubMed  Google Scholar 

  9. Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer.Cancer 1994;73:2048–52.

    CAS  PubMed  Google Scholar 

  10. Fujimura T, Yonemura Y, Fushida S, et al. Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation.Cancer 1990;65:65–71.

    CAS  PubMed  Google Scholar 

  11. Leinard D, Lejeune F, Delmotte J, et al. High doses of rTNFα in combination with IFN-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.J Clin Oncol 1992;10:52–60.

    Google Scholar 

  12. Fraker DL, Alexander HR. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma. In: DeVita VT, Hellman S, Rosenberg SA, eds.Important advances in oncology. Philadelphia: JB Lippincott, 1994:179–92.

    Google Scholar 

  13. Fraker DL, Alexander HR. The use of tumor necrosis factor in isolated limb perfusions for melanoma and sarcoma. In: DeVita V, Hellman S, Rosenberg SA, eds.Principles and practice of oncology. Philadelphia: JB Lippincott, 1993.

    Google Scholar 

  14. Räth U, Kaufmann M, Schmid H, et al. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites.Eur J Cancer 1991;27:121–5.

    PubMed  Google Scholar 

  15. Hardy J, Jones A, Gore ME, Viner C, Selby P, Wiltshaw E. Treatment of advanced ovarian cancer with intraperitoneal tumour necrosis factor.Eur J Cancer 1990;26:771.

    CAS  PubMed  Google Scholar 

  16. Fraker DL, Alexander HR, Pass HI. Biologic therapy with TNF: systemic administration and isolation-perfusion. In: DeVita V, Hellman S, Rosenberg SA, eds.Biologic therapy of cancer. Philadelphia: JB Lippincott, 1995:329–45.

    Google Scholar 

  17. Markman M, Reichman B, Ianotti N, et al. Phase I trial of recombinant tumor necrosis factor administered by the intraperitoneal route.Reg Cancer Treat 1989;2:174–7.

    Google Scholar 

  18. Raeth U, Schmid H, Karck U, Kempeni J, Schlick E, Kaufmann M. Phase II trial of recombinant human tumor necrosis factorα (rHuTNF) in patients with malignant ascites from ovarian carcinomas and non-ovarian tumors with intraperitoneal spread.Proc ASCO 1991;10:187.

    Google Scholar 

  19. Yamauchi N, Watanabe N, Maeda M, et al. Mechanism of synergistic cytotoxic effect between tumor necrosis factor and hyperthermia.Jpn J Cancer Res 1992;83:540–5.

    CAS  PubMed  Google Scholar 

  20. Klostergaard J, Leroux E, Siddik ZH, Khodadadian M, Tomasovic SP. Enhanced sensitivity of human colon tumor cell lines in vitro in response to thermochemoimmunotherapy.Cancer Res 1992;52:5271–7.

    CAS  PubMed  Google Scholar 

  21. Flessner MF, Dedrick RL. Intraperitoneal chemotherapy. In: Gokal R, Nolph KD, eds.The textbook of peritoneal dialysis. The Netherlands: Kluwer Academic, 1994:769–89.

    Google Scholar 

  22. Markman M. Intraperitoneal chemotherapy for malignant diseases of the gastrointestinal tract.Surg Gynecol Obstet 1987;164:89–93.

    CAS  PubMed  Google Scholar 

  23. Barloie B, Corry PM, Drewinko B. In vitro thermotherapy of colon cancer cells with cis-dischlorodiammineplatinum(II) and mitomycin C.Chem Biol Interact 1987;61:1.

    Google Scholar 

  24. Herman TS, Teicher BA, Cathcart KNS, Kaufman ME, Lee JB, Lee MN. Effect of hyperthermia on cis-diamminedichlorplatinum(II), (rhodamine123)2[tetrachloroplatinum(II)], in a human squamous cell carcinoma line and cis-diamminedichloroplatinum(II)-resistant subline.Cancer Res 1988;48:5101.

    CAS  PubMed  Google Scholar 

  25. Overgaard J, Radacic MM, Gran C. Interaction of hyperthermia and cis-diamminedichloroplatinum(II) alone or combined with radiation in a C3H mammary carcinoma in vivo.Cancer Res 1991;51:707.

    CAS  PubMed  Google Scholar 

  26. Alberts DS, Peng YM, Chen G, Moon TE, Cetas TC, Hoeschele JD. Therapeutic synergism of hyperthermia-cisplatinum in a mouse model.J Natl Cancer Inst 1980;65:455.

    CAS  PubMed  Google Scholar 

  27. Wondergem J, Bulger RE, Strebel FR, et al. Effect of cis-diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury.Cancer Res 1988;48:440–6.

    CAS  PubMed  Google Scholar 

  28. Ohno S, Siddik ZH, Kido Y, Zwelling LA, Bull JM. Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cis-platin-induced cytotoxicity in L1210 cells.Cancer Chemother Pharmacol 1994;34:302–6.

    CAS  PubMed  Google Scholar 

  29. Reed E, Parker RJ, Gill I, et al. Platinum-DNA adduct in leukocyte DNA of a chohort of 49 patients with 24 different types of malignancies.Cancer Res 1993;53:3694–9.

    CAS  PubMed  Google Scholar 

  30. McGahan MC, Tyczkowska K. The determination of platinum in biological materials by electrothermal atomic absorption spectroscopy.Spectrochim Acta 1987;42B:665–8.

    CAS  Google Scholar 

  31. Flamm WG, Birnstiel ML, Walker PMB.Subcellular components: preparation and fractionation. London: Butterworth, 1969.

    Google Scholar 

  32. Reed E, Sauerhoff S, Poirier MC. Quantitation of platinum-DNA binding in human tissues following therapeutic levels of drug exposure.Atomic Spectroscopy 1988;9:93–5.

    CAS  Google Scholar 

  33. Hahn GM. Metabolic aspects of the role of hyperthermia in mammalian cell inactivation and their possible relevance to cancer treatment.Cancer Res 1974;34:3117–23.

    CAS  PubMed  Google Scholar 

  34. Dudar TE, Jain RK. Differential response of normal and tumor microcirculation to hyperthermia.Cancer Res 1984;44:605–12.

    CAS  PubMed  Google Scholar 

  35. Joiner MC, Steel GG, Stephens TC. Response of two mouse tumours to hyperthermia with CCNU or melphalan.Br J Cancer 1982;45:17–26.

    CAS  PubMed  Google Scholar 

  36. Kitamura K, Kuwano H, Matsuda H, Toh Y, Masuda H, Sugimachi K. Synergistic effects of intratumor administration of cis-diamminedichloroplatinum(II) combined with local hyperthermia in melanoma bearing mice.J Surg Oncol 1992;51:188–94.

    CAS  PubMed  Google Scholar 

  37. Ohno S, Strebetl FR, Stephens C, et al. Increased therapeutic efficacy induced by tumor necrosis factor α combined with platinum complexes and whole-body hyperthermia in rats.Cancer Res 1992;52:4096–101.

    CAS  PubMed  Google Scholar 

  38. Los G, Sminia P, Wondergem J, et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats.Eur J Cancer 1991;4:472–7.

    Google Scholar 

  39. Bonavida B: TNF as immunomodulatory agent.Immunol Series 1992;56:315–29.

    CAS  Google Scholar 

  40. Parker RJ, Eastman A, Bostick-Burton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.J Clin Invest 1991;87:772–7.

    CAS  PubMed  Google Scholar 

  41. Howell SB, Pfeifle CE, Wung WE, Olshen RA. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection.Cancer Res 1983;43:1426–31.

    CAS  PubMed  Google Scholar 

  42. Alberts DS, Liu PY, Hannigan EV, et al. Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) vs IV CDDP/IV CPA in patients (PTS) with optimal disease stage III ovarian cancer: a SWOG-GOG-ECOG intergroup study (INT 0051) [Abstract].Am Soc Clin Oncol 1995;14:273.

    Google Scholar 

  43. Zakris EL, Dewhirst MW, Riviere JE, Hoopes PJ, Page RL, Oleson JR. Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia.J Clin Oncol 1987;5:1613–20.

    CAS  PubMed  Google Scholar 

  44. Raeth U, Schmid H, Hofmann J, et al. Intraperitoneal (i.p.) application of recombinant human tumor necrosis factor (rHuTNF) as an effective palliative treatment of malignant ascites from ovarian and gastroenteropancreatic carcinomas.Proc ASCO 1989;8:181.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgical Metabolism Section, Surgery Branch, National Cancer Institute, National Institutes of Health, 20892, Bethesda, MD, USA

    Joseph F. Buell MD, Eddie Reed MD, Kang Bo Lee MD, Ricardo J. Parker PhD, David J. Venzon PhD, Katsumi Amikura MD, W. Scott Arnold MD, Douglas L. Fraker MD &  H. Richard Alexander MD

Authors
  1. Joseph F. Buell MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eddie Reed MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kang Bo Lee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ricardo J. Parker PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David J. Venzon PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Katsumi Amikura MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W. Scott Arnold MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Douglas L. Fraker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. Richard Alexander MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buell, J.F., Reed, E., Lee, K.B. et al. Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells. Annals of Surgical Oncology 4, 141–148 (1997). https://doi.org/10.1007/BF02303797

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02303797

Key Words

Search

Navigation